Comparison of Therapeutic Efficacy for Neonatal ABO Hemolytic Disease Treated with Intravenous Immunoglobin G by Different Modes of Administration.

Yun-feng Liu; Chao-chun Zou; Hua-qin Yang; Li-jiang Lou

Return

Comparison of Therapeutic Efficacy for Neonatal ABO Hemolytic Disease Treated with Intravenous Immunoglobin G by Different Modes of Administration.

Author: Yun-Feng LIU ¹ ; Chao-Chun ZOU ² ; Hua-Qin YANG ³ ; Li-Jiang LOU ⁴
Author Information

1. Department of Endocrinology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310051, Zhejiang Province, China.
2. Department of Endocrinology, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310051, Zhejiang Province, China. E-mail: liu4380@126.com.
3. Department of Pediatrics, The First Hospital of Ninghai, Ninghai 315600, Zhejiang Province, China.
4. Department of Hematology, The First Hospital of Ninghai, Ninghai 315600, Zhejiang Province, China.
Publication Type:Journal Article
From: Journal of Experimental Hematology 2016;24(6):1842-1845
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo compare the therapeutic efficacy of patients with neonatal ABO hemolytic disease treated with introvenous immunoglobin G (IVIG) by different modes of administration.
METHODSNinety-three in patients with neonatal ABO hemolytic disease treated in our hospital were divided into group A (31 cases), B(31 cases) and C (31 cases). Based on basic treatment, the patients in group A were treated by a single high dose of IVIG (1 g/kg), patients in group B were treated by multiple low-dose of IVIG (0.5 g/kg), and the patients in group C treated by placebo without IVIG used as controls. The phototherapy time, jaundice time in 3 groups were observed; the total bilirubin levels in 3 groups were compared before and after treatment; the incidence of anemia, the rate of blood transfusion and the occurrence of bilirubin encephalopathy were compared after treatment between 3 groups.
RESULTSThe phototherapy time, jaundice time in group A were statistically significantly shorter than those in the group B and C (P<0.05), but there was not statistical significantly difference between group B and C(P>0.05). Before treatment, serum TBIL level in 3 groups was not significantly different (P>0.05); and after treatment for 24 h and 48 h, the serum TBIL levels in group A were significantly lower than that in group B and C (P<0.05); after treatment for 72 h, the serum TBIL level in group A was all lower than 34.2 µmol/L; before treatment, Hb levels in 3 groups were not significantly different (P>0.05); Hb level in group A was significantly higher than that in group B and C after treatment for 24 h, 48 h and 72 h (P<0.05). The incidence of anemia in group A after treatment was significantly lower than that in group B and C, and that in group B significantly lower than that in group C(P<0.05). The rate of blood transfusion in group A was significantly lower than that in the group B and C (P<0.05); the rate of blood transfusion was not statistically significantly different between group B and C(P>0.05).
CONCLUSIONThe single high dose of IVIG infusion can effectively reduce the serum TBIL level, shorten treatment time and reduce the incidence of anemia and blood transfusion, so the therapeutic efficacy is significantly improved.